Last updated: February 28, 2026
What is the Drug?
NDC 00115-9930 corresponds to Vasopressin, a hormone used primarily for vasodilatory shock, cardiac arrest, and diabetes insipidus. It is packaged in injectable form, typically for hospital use.
Current Market Landscape
Market Size and Usage
- The global vasopressin market was valued at approximately USD 1.2 billion in 2022.
- Estimated annual volume for hospital injections: 50 million units.
- Main application: intensive care units and emergency medicine.
Key Competitors
| Company |
Product Name |
Market Share |
Notes |
| Ferring Pharmaceuticals |
Vasostrict |
50% |
Market leader, US and Europe markets |
| Sandoz (Novartis) |
Vasopressin Injection |
25% |
Competing product, primarily in US and Europe |
| Others |
Various generics |
25% |
Smaller players, niche markets |
Regulatory Environment
- Approvals: FDA (US), EMA (Europe), and other regional agencies.
- Patent status: No active patents; off-patent since 2010.
- Reimbursement: Medicare and private insurers cover the drug with hospital administration codes.
Distribution Channels
- Primarily sold through hospital supply chains.
- High-volume transactions facilitated via negotiated contracts.
Price Trends and Projections
Current Pricing
- Per vial: USD 20–30, depending on purchase volume and supplier.
- Bulk purchase discounts are common for institutional buyers, reducing unit price by up to 20%.
Price Drivers
- Manufacturing costs: Stable, with minor fluctuations in raw materials (e.g., peptide synthesis chemicals).
- Supply chain factors: Shortages are rare but can cause temporary price spikes.
- Competitive dynamics: Entry of generics stabilizes and decreases prices.
Price Forecast for 2023–2027
| Year |
Projected Average Price per Vial |
Key Factors |
| 2023 |
USD 26 |
Stable supply, no new entrants |
| 2024 |
USD 24–25 |
Generic penetration, continued competitive pressure |
| 2025 |
USD 23 |
Increased generic market share reduces prices |
| 2026 |
USD 22–23 |
Market stabilization, manufacturing efficiencies |
| 2027 |
USD 21–22 |
Further generic entry, potential biosimilar developments |
Potential Market Risks
- Regulatory changes affecting hospital formularies.
- Supply chain disruptions influencing availability.
- Price erosion from increased generic competition.
Opportunities and Challenges
Opportunities
- Growing demand in emerging markets citing rising hospital capacity.
- Development of biosimilar vasopressin products could lower prices further.
- Potential for alternate delivery formulations (e.g., nasal spray) to expand use.
Challenges
- Slow adoption of alternative therapies, such as terlipressin.
- Price pressures from payers controlling hospital drug budgets.
- Limited patient-facing marketing due to hospital-based administration.
Key Takeaways
- NDC 00115-9930 (vasopressin) remains a stable market with a size around USD 1.2 billion.
- The product is largely commoditized following patent expiration, resulting in consistent price attrition.
- Price per vial is expected to decline gradually, reaching USD 21–22 by 2027.
- Market share remains concentrated among a few large players but faces threat from generics and biosimilars.
- Regulatory and supply chain factors are the main external influences on pricing.
FAQs
1. What factors influence the price of vasopressin?
Manufacturing costs, generic competition, hospital purchasing practices, supply chain stability, and regulatory changes.
2. How will market competition affect future prices?
Increasing generic entries are expected to continue driving prices downward, especially after patent expiry.
3. Are biosimilars a threat to existing vasopressin products?
Potentially, if biosimilars meet regulatory standards and gain hospital acceptance, they could further reduce prices.
4. What is the significance of regional regulation?
Different regulations may influence product availability and pricing, especially in emerging versus developed markets.
5. How sustainable is the current market size?
Given the essential nature of vasopressin in critical care, the market size remains relatively stable, though pricing may decline.
References
- MarketsandMarkets. (2022). Vasopressin Market by Application, End-User, and Region—Global Forecast to 2027.
- IQVIA. (2022). Hospital and Retail Pharmaceutical Data.
- U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Status.
- Statista. (2023). Hospital Drug Market Trends.
- European Medicines Agency. (2022). Regulatory data on Vasopressin formulations.
